Stereotactic Radiotherapy for Brain Metastases: A Detailed Overview of Indications, Dose Fractionation, Technological Advances, and Emerging Combination Therapies - Scorecard - MDSpire
Advertisement
Stereotactic Radiotherapy for Brain Metastases: A Detailed Overview of Indications, Dose Fractionation, Technological Advances, and Emerging Combination Therapies
Clinical Scorecard: Stereotactic Radiotherapy for Brain Metastases: A Detailed Overview of Indications, Dose Fractionation, Technological Advances, and Emerging Combination Therapies
At a Glance
Category
Detail
Condition
Brain Metastases
Key Mechanisms
High precision, rapid dose fall-off, local control, preservation of neurocognitive function.
Target Population
Patients with oligometastatic brain disease and multiple brain metastases.
Care Setting
Multidisciplinary treatment settings.
Key Highlights
Stereotactic radiotherapy (SRT) is increasingly adopted for brain metastases due to its precision and efficacy.
Combination of SRT with systemic therapies shows promise in maintaining intracranial control.
Histological type influences treatment outcomes and requires tailored approaches.
Guideline-Based Recommendations
Diagnosis
Consider histological type and natural history when diagnosing brain metastases.
Management
SRT is a key component of standard treatment for oligometastatic brain metastases.
Monitoring & Follow-up
Monitor neurocognitive function and local control rates post-treatment.
Risks
Combination of SRT with whole brain radiotherapy (WBRT) may worsen neurocognitive function without improving overall survival.
Patient & Prescribing Data
Patients with various histologies of brain metastases, including non-small cell lung cancer, melanoma, and breast cancer.
Histology-specific treatment regimens are necessary for optimizing outcomes.
Clinical Best Practices
Utilize individualized radiotherapy decisions based on tumor biology and molecular subtype.
Consider the use of targeted and immunotherapies in conjunction with SRT.
